Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer.

Literature DB >> 8252511

Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer.

L Denis¹, G P Murphy.

Abstract

Entities: Disease Species

Mesh：

Substances：

Year: 1993 PMID： 8252511 DOI： 10.1002/1097-0142(19931215)72:12+<3888::aid-cncr2820721726>3.0.co;2-b

Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.860

Keyword Cloud
Cited

× No keyword cloud information.

33 in total

Review 1. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors: Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal: Invest New Drugs Date: 2002-05 Impact factor: 3.850

2. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors: Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal: Mol Ther Date: 2003-11 Impact factor: 11.454

3. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.

Authors: Élcio Dias Silva; Ubirajara Ferreira; Wagner Matheus; Eliney F Faria; Gustavo D Silva; Minori Saito; Auro A S de Souza; Azuil Laranjo; Otavio Clark; Luis Alberto Magna; Lísias Nogueira Castilho; Leonardo Oliveira Reis
Journal: Int Urol Nephrol Date: 2012-08 Impact factor: 2.370

Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer.

Review 1. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

2. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

3. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.

4. The current status of adjuvant hormonal therapy combined with radiation therapy for localised prostate cancer.

5. Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer.

6. [Antihormonal therapy in prostate cancer : Side effects].

Review 7. Clinical and economic considerations in the treatment of prostate cancer.

8. Expression and initial promoter characterization of PCAN1 in retinal tissue and prostate cell lines.

9. Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

10. Pathogenesis of prostate cancer and hormone refractory prostate cancer.